Stock Events

Bionano Genomics 

$0.64
984
+$0+0% Friday 18:09

Statistics

Day High
0.66
Day Low
0.63
52W High
4.19
52W Low
0.51
Volume
32,556
Avg. Volume
63,764
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.24
-0.86
-0.49
-0.11
Expected EPS
-0.64
Actual EPS
-0.6

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A4K.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacific Biosciences of California
PACB
Mkt Cap356.79M
Pacific Biosciences offers long-read sequencing technologies that compete with Bionano's optical genome mapping solutions for complex genetic research and diagnostics.
Illumina
ILMN
Mkt Cap17.29B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics market space that Bionano targets.
Thermo Fisher Scientific
TMO
Mkt Cap206.16B
Thermo Fisher Scientific offers a broad range of instruments and reagents for genomic research, including next-generation sequencing, competing with Bionano's genomic analysis technologies.
Agenus
AGEN
Mkt Cap317.72M
Agilent Technologies provides instruments, software, services, and consumables for the entire laboratory workflow, including genomics research, competing with Bionano's offerings.
Qiagen NV
QGEN
Mkt Cap9.38B
Qiagen offers sample to insight solutions, including next-generation sequencing and molecular diagnostics that compete with Bionano's genomic analysis solutions.
Intellia Therapeutics
NTLA
Mkt Cap2.2B
Intellia Therapeutics is involved in CRISPR/Cas9 technology for genome editing, which competes indirectly with Bionano's genomic mapping and analysis technologies by offering alternative approaches to genetic research and diagnostics.
Editas Medicine
EDIT
Mkt Cap377.47M
Editas Medicine operates in the genome editing space using CRISPR technology, offering a competitive alternative to Bionano's genomic analysis and mapping solutions.
CRISPR Therapeutics
CRSP
Mkt Cap4.51B
CRISPR Therapeutics is focused on developing gene-based medicines using CRISPR/Cas9 technologies, indirectly competing with Bionano's genomic analysis tools by providing alternative methods for genetic research.
Twist Bioscience
TWST
Mkt Cap2.82B
Twist Bioscience operates in the synthetic biology and genomics field, producing synthetic DNA that is used in genetic research, competing with Bionano's genomic analysis and mapping technologies.

About

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Employees
299
Country
United States
ISIN
US09075F3055
WKN
000A2JRLZ

Listings